Dosimetric Effects of Air Cavities for MRI-Guided Online Adaptive Radiation Therapy (MRgART) of Prostate Bed after Radical Prostatectomy
J Clin Med. 2022 Jan 12;11(2):364. doi: 10.3390/jcm11020364.ABSTRACTPURPOSE: To evaluate dosimetric impact of air cavities and their corresponding electron density correction for 0.35 tesla (T) Magnetic Resonance-guided Online Adaptive Radiation Therapy (MRgART) of prostate bed patients.METHODS: Three 0.35 T MRgRT plans (anterior-posterior (AP) beam, AP-PA beams, and clinical intensity modulated radiation therapy (IMRT)) were generated on a prostate bed patient's (Patient A) planning computed tomography (CT) with artificial rectal air cavities of various sizes (0-3 cm, 0.5 cm increments). Furthermore, two 0.35 T MRgART pla...
Source: Clinical Prostate Cancer - January 21, 2022 Category: Cancer & Oncology Authors: Jonathan Pham Minsong Cao Stephanie M Yoon Yu Gao Amar U Kishan Yingli Yang Source Type: research

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print.ABSTRACTPURPOSE: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now report long-term outcomes (LTOs) and correlative science end points.PATIENTS AND METHODS: The Kaplan-Meier method was used to estimate LTOs in 443 patients who initiated study treatment. Log-rank tests and Cox pro...
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Jonathan H Shepherd Karla Ballman Mei-Yin C Polley Jordan D Campbell Cheng Fan Sara Selitsky Aranzazu Fernandez-Martinez Joel S Parker Katherine A Hoadley Zhiyuan Hu Yan Li Matthew G Soloway Patricia A Spears Baljit Singh Sara M Tolaney George Somlo Elisa Source Type: research

Nandrolone-Induced Tumor Progression in Hormone-Sensitive Prostate Cancer
We describe a patient of a recurrent hormone-sensitive prostate cancer who was on salvage androgen deprivation therapy with degarelix and developed rapid progression after over-the-counter nandrolone injections.PMID:35044958 | DOI:10.1097/RLU.0000000000004058 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Shikha Goyal Renu Madan Narendra Kumar Source Type: research

Dosimetric advantages of daily adaptive strategy in IMPT for high-risk prostate cancer
J Appl Clin Med Phys. 2022 Jan 19:e13531. doi: 10.1002/acm2.13531. Online ahead of print.ABSTRACTPURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity-modulated proton therapy (IMPT) for high-risk prostate cancer by comparing estimated doses of the conventional non-adaptive radiotherapy (NART) that irradiates according to an original treatment plan through the entire treatment and the DART that uses an adaptive treatment plan generated by using daily CT images acquired before each treatment.METHODS: Twenty-three patients with prostate cancer were included. A treatment plan with 6...
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Hiroshi Tamura Keiji Kobashi Kentaro Nishioka Takaaki Yoshimura Takayuki Hashimoto Shinichi Shimizu Yoichi M Ito Yoshikazu Maeda Makoto Sasaki Kazutaka Yamamoto Hiroyasu Tamamura Hidefumi Aoyama Hiroki Shirato Source Type: research

PCaGuard: A Software Platform to Support Optimal Management of Prostate Cancer
CONCLUSION: This platform handles data to estimate the risk of prostate cancer detection using current state-of-the-art in eHealth systems and services while fusing emerging multidisciplinary and intersectoral approaches. This work offers the research community an open architecture framework that encourages the broader adoption of more robust and comprehensive systems in standard clinical practice.PMID:35045583 | DOI:10.1055/s-0041-1741481 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Ioannis Tamposis Ioannis Tsougos Anastasios Karatzas Katerina Vassiou Marianna Vlychou Vasileios Tzortzis Source Type: research

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506. Online ahead of print.ABSTRACTPURPOSE: CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now report long-term outcomes (LTOs) and correlative science end points.PATIENTS AND METHODS: The Kaplan-Meier method was used to estimate LTOs in 443 patients who initiated study treatment. Log-rank tests and Cox pro...
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Jonathan H Shepherd Karla Ballman Mei-Yin C Polley Jordan D Campbell Cheng Fan Sara Selitsky Aranzazu Fernandez-Martinez Joel S Parker Katherine A Hoadley Zhiyuan Hu Yan Li Matthew G Soloway Patricia A Spears Baljit Singh Sara M Tolaney George Somlo Elisa Source Type: research

Nandrolone-Induced Tumor Progression in Hormone-Sensitive Prostate Cancer
We describe a patient of a recurrent hormone-sensitive prostate cancer who was on salvage androgen deprivation therapy with degarelix and developed rapid progression after over-the-counter nandrolone injections.PMID:35044958 | DOI:10.1097/RLU.0000000000004058 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Shikha Goyal Renu Madan Narendra Kumar Source Type: research

Dosimetric advantages of daily adaptive strategy in IMPT for high-risk prostate cancer
J Appl Clin Med Phys. 2022 Jan 19:e13531. doi: 10.1002/acm2.13531. Online ahead of print.ABSTRACTPURPOSE: To evaluate the dosimetric advantages of daily adaptive radiotherapy (DART) in intensity-modulated proton therapy (IMPT) for high-risk prostate cancer by comparing estimated doses of the conventional non-adaptive radiotherapy (NART) that irradiates according to an original treatment plan through the entire treatment and the DART that uses an adaptive treatment plan generated by using daily CT images acquired before each treatment.METHODS: Twenty-three patients with prostate cancer were included. A treatment plan with 6...
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Hiroshi Tamura Keiji Kobashi Kentaro Nishioka Takaaki Yoshimura Takayuki Hashimoto Shinichi Shimizu Yoichi M Ito Yoshikazu Maeda Makoto Sasaki Kazutaka Yamamoto Hiroyasu Tamamura Hidefumi Aoyama Hiroki Shirato Source Type: research

PCaGuard: A Software Platform to Support Optimal Management of Prostate Cancer
CONCLUSION: This platform handles data to estimate the risk of prostate cancer detection using current state-of-the-art in eHealth systems and services while fusing emerging multidisciplinary and intersectoral approaches. This work offers the research community an open architecture framework that encourages the broader adoption of more robust and comprehensive systems in standard clinical practice.PMID:35045583 | DOI:10.1055/s-0041-1741481 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 19, 2022 Category: Cancer & Oncology Authors: Ioannis Tamposis Ioannis Tsougos Anastasios Karatzas Katerina Vassiou Marianna Vlychou Vasileios Tzortzis Source Type: research

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
CONCLUSION: The study met the primary end point. The combination of imatinib and binimetinib is effective with manageable toxicity and warrants further evaluation in direct comparison with imatinib in frontline treatment of GIST.PMID:35041493 | DOI:10.1200/JCO.21.02029 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 18, 2022 Category: Cancer & Oncology Authors: Ping Chi Li-Xuan Qin Bastien Nguyen Ciara M Kelly Sandra P D'Angelo Mark A Dickson Mrinal M Gounder Mary L Keohan Sujana Movva Benjamin A Nacev Evan Rosenbaum Katherine A Thornton Aimee M Crago Sam Yoon Gary Ulaner Randy Yeh Moriah Martindale Haley T Phel Source Type: research

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
CONCLUSION: The study met the primary end point. The combination of imatinib and binimetinib is effective with manageable toxicity and warrants further evaluation in direct comparison with imatinib in frontline treatment of GIST.PMID:35041493 | DOI:10.1200/JCO.21.02029 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 18, 2022 Category: Cancer & Oncology Authors: Ping Chi Li-Xuan Qin Bastien Nguyen Ciara M Kelly Sandra P D'Angelo Mark A Dickson Mrinal M Gounder Mary L Keohan Sujana Movva Benjamin A Nacev Evan Rosenbaum Katherine A Thornton Aimee M Crago Sam Yoon Gary Ulaner Randy Yeh Moriah Martindale Haley T Phel Source Type: research

A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere < sup > Ⓡ < /sup > (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy
Curr Ther Res Clin Exp. 2021 Dec 16;96:100659. doi: 10.1016/j.curtheres.2021.100659. eCollection 2022.ABSTRACTBACKGROUND: Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, and prostate cancer.OBJECTIVE: This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel.METHODS: Patients who received Alvotere as a part of their chemotherapy reg...
Source: Clinical Prostate Cancer - January 17, 2022 Category: Cancer & Oncology Authors: Farhad Shahi Farahnaz Vafaeezadeh Nafiseh Ansarinejad Alireza Ahmadi Ali Shahriari-Ahmadi Alireza Ghazizadeh Hassanali Vahedian Ardakani Mohammad Reza Ravanbod Sharareh Seifi Mohammad Foratyazdi Seyed Asadollah Mousavi Mansour Rajabi Vahid Hossein Rahimi Source Type: research

Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed.PMID:35036588 | PMC:PMC8749177 | DOI:10.1016/j.ctro.2021.12.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 17, 2022 Category: Cancer & Oncology Authors: Ben G L Vanneste Ludy Lutgens Evert J Van Limbergen Source Type: research

A Post-Marketing Surveillance Study to Evaluate the Safety Profile of Alvotere < sup > Ⓡ < /sup > (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy
Curr Ther Res Clin Exp. 2021 Dec 16;96:100659. doi: 10.1016/j.curtheres.2021.100659. eCollection 2022.ABSTRACTBACKGROUND: Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, and prostate cancer.OBJECTIVE: This is a Phase IV study to evaluate the safety profile of docetaxel (Alvotere; NanoAlvand, Iran) in Iranian patients diagnosed with different types of cancers receiving chemotherapy regimens with docetaxel.METHODS: Patients who received Alvotere as a part of their chemotherapy reg...
Source: Clinical Prostate Cancer - January 17, 2022 Category: Cancer & Oncology Authors: Farhad Shahi Farahnaz Vafaeezadeh Nafiseh Ansarinejad Alireza Ahmadi Ali Shahriari-Ahmadi Alireza Ghazizadeh Hassanali Vahedian Ardakani Mohammad Reza Ravanbod Sharareh Seifi Mohammad Foratyazdi Seyed Asadollah Mousavi Mansour Rajabi Vahid Hossein Rahimi Source Type: research

Evaluation of hyaluronic acid gel dissolution with hyaluronidase in an in-vitro prostate cancer model
CONCLUSIONS: A dose response was observed by HAS injection: highest volumes of HAS dissolute most swiftly. Using a ratio of HA:HAS of 1:2 results in a decrease to half of initial volume within 24 h. This is of special interest when used in clinical practice following erroneous positioning, and dissolution is urgently needed.PMID:35036588 | PMC:PMC8749177 | DOI:10.1016/j.ctro.2021.12.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 17, 2022 Category: Cancer & Oncology Authors: Ben G L Vanneste Ludy Lutgens Evert J Van Limbergen Source Type: research

Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer
Clin Oncol (R Coll Radiol). 2022 Jan 12:S0936-6555(21)00519-7. doi: 10.1016/j.clon.2021.12.020. Online ahead of print.ABSTRACTAIMS: The benefits of neoadjuvant androgen deprivation therapy (nADT) in the management of intermediate- and high-risk prostate cancer patients have been well-established. The aim of this study was to identify radiomic prognostic features derived from routine anatomic magnetic resonance imaging (MRI) sequences that can predict the response of the prostate cancer to nADT.MATERIALS AND METHODS: Patients with intermediate- and high-risk prostate cancer (with one of clinical stage ≥ T2c, Gleason scor...
Source: Clinical Prostate Cancer - January 16, 2022 Category: Cancer & Oncology Authors: H Tharmalingam Y M Tsang R Alonzi W Beasley N J Taylor A McWilliam A Padhani A Choudhury P J Hoskin Source Type: research

Prostate Cancer Masquerading as Colon Adenocarcinoma
Clin Gastroenterol Hepatol. 2022 Jan 13:S1542-3565(22)00032-5. doi: 10.1016/j.cgh.2022.01.009. Online ahead of print.NO ABSTRACTPMID:35033639 | DOI:10.1016/j.cgh.2022.01.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 16, 2022 Category: Cancer & Oncology Authors: Preet Patel Cheng Huang Erik C von Rosenvinge Source Type: research

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability
Clin Genitourin Cancer. 2021 Dec 24:S1558-7673(21)00245-7. doi: 10.1016/j.clgc.2021.11.015. Online ahead of print.NO ABSTRACTPMID:35027313 | DOI:10.1016/j.clgc.2021.11.015 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Aline B L Gongora Catherine H Marshall Pedro Isaacsson Velho Carlos D H Lopes Jos é F Marin Anamaria A Camargo Diogo A Bastos Emmanuel S Antonarakis Source Type: research

Single Positive Core Prostate Cancer at Biopsy: Clinicopathological Implications and Risk Factors for Adverse Pathological Outcomes
CONCLUSIONS: Single positive core PCa have clinically significance in the radical prostatectomy specimens, with considerable rates of undergrading for the GS, PNI, PSMs, ECE and SVI. For patients with single positive core PCa, other prognostic factors must be considered in the treatment plan.PMID:35027314 | DOI:10.1016/j.clgc.2021.12.013 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Qiqi Mao Yiwei Lin Dan Xia Shuo Wang Hai Jiang Source Type: research

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability
Clin Genitourin Cancer. 2021 Dec 24:S1558-7673(21)00245-7. doi: 10.1016/j.clgc.2021.11.015. Online ahead of print.NO ABSTRACTPMID:35027313 | DOI:10.1016/j.clgc.2021.11.015 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Aline B L Gongora Catherine H Marshall Pedro Isaacsson Velho Carlos D H Lopes Jos é F Marin Anamaria A Camargo Diogo A Bastos Emmanuel S Antonarakis Source Type: research

Single Positive Core Prostate Cancer at Biopsy: Clinicopathological Implications and Risk Factors for Adverse Pathological Outcomes
CONCLUSIONS: Single positive core PCa have clinically significance in the radical prostatectomy specimens, with considerable rates of undergrading for the GS, PNI, PSMs, ECE and SVI. For patients with single positive core PCa, other prognostic factors must be considered in the treatment plan.PMID:35027314 | DOI:10.1016/j.clgc.2021.12.013 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Qiqi Mao Yiwei Lin Dan Xia Shuo Wang Hai Jiang Source Type: research

Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability
Clin Genitourin Cancer. 2021 Dec 24:S1558-7673(21)00245-7. doi: 10.1016/j.clgc.2021.11.015. Online ahead of print.NO ABSTRACTPMID:35027313 | DOI:10.1016/j.clgc.2021.11.015 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Aline B L Gongora Catherine H Marshall Pedro Isaacsson Velho Carlos D H Lopes Jos é F Marin Anamaria A Camargo Diogo A Bastos Emmanuel S Antonarakis Source Type: research

Single Positive Core Prostate Cancer at Biopsy: Clinicopathological Implications and Risk Factors for Adverse Pathological Outcomes
CONCLUSIONS: Single positive core PCa have clinically significance in the radical prostatectomy specimens, with considerable rates of undergrading for the GS, PNI, PSMs, ECE and SVI. For patients with single positive core PCa, other prognostic factors must be considered in the treatment plan.PMID:35027314 | DOI:10.1016/j.clgc.2021.12.013 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 14, 2022 Category: Cancer & Oncology Authors: Qiqi Mao Yiwei Lin Dan Xia Shuo Wang Hai Jiang Source Type: research

Incidental Spinal Meningioma on an 18F-Fluciclovine PET/CT
We present the 18F-fluciclovine PET/CT of a 60-year-old man undergoing evaluation of biochemically recurrent prostate cancer with incidental radiotracer uptake in the thoracic spinal canal, which was proven to be a World Health Organization grade I spinal meningioma on surgical pathology. 18F-fluciclovine and 18F-FDG PET/CT images of a 60-year-old man with biochemically recurrent prostate cancer prostate cancer with a prostate-specific antigen of 14.4 ng/mL, 7 years after primary external beam radiation followed by a prostate-specific antigen nadir of 1.6 ng/mL, are presented.PMID:35025777 | DOI:10.1097/RLU.000000000000404...
Source: Clinical Prostate Cancer - January 13, 2022 Category: Cancer & Oncology Authors: Charles Marcus Kristen Baugnon David M Schuster Source Type: research

MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
CONCLUSIONS: We provide evidence on the role of MALAT1 in PCa tumorigenesis and progression. Also, we identify a direct interaction between miR-423-5p and MALAT1, which results in the suppression of MALAT1 action in PCa.PMID:35016717 | PMC:PMC8751098 | DOI:10.1186/s13046-021-02233-w (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Carmela Ferri Anna Di Biase Marco Bocchetti Silvia Zappavigna Sarah Wagner Pauline Le Vu Amalia Luce Alessia Maria Cossu Jayakumar Vadakekolathu Amanda Miles David J Boocock Alex Robinson Melanie Schwerdtfeger Virginia Tirino Federica Papaccio Michele Car Source Type: research

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer
Clin Genitourin Cancer. 2021 Dec 10:S1558-7673(21)00235-4. doi: 10.1016/j.clgc.2021.12.004. Online ahead of print.NO ABSTRACTPMID:35016887 | DOI:10.1016/j.clgc.2021.12.004 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Jeroen van Dorp Maurits L van Montfoort Nick van Dijk Ingrid Hofland Jeantine M de Feijter Andries M Bergman Kees Hendricksen Henk G van der Poel Bas W G van Rhijn Michiel S van der Heijden Source Type: research

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
CONCLUSION: Like patients, different mCRPC cell lines exhibit significant variability regarding CDDP tolerance. The presented in vitro data suggest that previous radiation treatment may be associated with a moderate sensitization to CDDP in an isogenic and age-matched setting. Therefore, previous radiotherapy or docetaxel chemotherapy might be no contraindication against initiation of platinum chemotherapy in selected mCRPC patients.PMID:35020044 | DOI:10.1007/s00432-022-03914-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Lukas Donix Holger H H Erb Claudia Peitzsch Anna Dubrovska Manuel Pfeifer Christian Thomas Susanne Fuessel Kati Erdmann Source Type: research

Cancer statistics, 2022
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.ABSTRACTEach year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases an...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Rebecca L Siegel Kimberly D Miller Hannah E Fuchs Ahmedin Jemal Source Type: research

68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003994. Online ahead of print.ABSTRACTA 63-year-old man with prostate cancer was treated with prostatectomy who had postoperative PSA of 0.6 ng/mL. A pelvic MRI, whole body bone scan, CT chest and abdomen exams did not show any residual or metastatic prostate disease. His PSA increased to 0.9 ng/mL in two months. A fluciclovine PET did not show any tracer avid metastatic or recurrent disease. A 0.7 cm non-fluciclovine-avid nodule at the left prostatectomy bed was considered benign. A 68Ga-PSMA-11 PET one month later showed avid radiotracer uptake within this nodule. Th...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Guofan Xu Yang Lu Source Type: research

Incidental Finding of Testicular Seminoma by 18F-Choline PET/CT in a Prostate Cancer Patient
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003988. Online ahead of print.ABSTRACTAn 80-year-old man with a history of prostate cancer, treated with radical prostatectomy and bilateral obturator nodal dissection, underwent an 18F-choline PET/CT because of biochemical recurrence. The scan revealed an intense focal uptake in the right testicle. A subsequent orchifunicumlectomy demonstrated the presence of a classic seminoma. At present, 18F-FDG PET/CT is useful for initial staging of testicular cancer and determining the viability of residual masses>3 cm after completion of treatment, especially in patients wit...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Anna Calabr ò Giovanni Bosio Emma Drera Raffaele Giubbini Francesco Bertagna Source Type: research

68Ga-DOTATATE and 68Ga-PSMA Uptake in Granulomatous Prostatitis
We report a case of a 78-year-old man with prostate lesions showing intense uptake of 18FDG, 68Ga-PSMA, and 68Ga-DOTATATE simultaneously, with heterogeneous enhancement on contrast-enhanced CT and abnormal signal changes on PET/MRI. It was finally diagnosed as granulomatous prostatitis. This case suggests that granulomatous prostatitis has a high uptake of various imaging agents and is easily misdiagnosed as prostate cancer.PMID:35020658 | DOI:10.1097/RLU.0000000000003971 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Dan Ruan Long Sun Source Type: research

Incidental Intrahepatic Hepatocellular Cholangiocarcinoma Detected on 68Ga-PSMA PET/CT
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003992. Online ahead of print.ABSTRACTA 69-year-old man with intermediate-risk prostate cancer and a mildly elevated prostate-specific antigen of 8.2 μg/L was referred for 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT for primary staging. An incidental intensely 68Ga-PSMA-avid hepatic focus was seen on PSMA PET and subsequent FDG PET/CT and MRI cholangiogram. This was confirmed to be hepatocellular cholangiocarcinoma on subsequent histopathological examination.PMID:35020661 | DOI:10.1097/RLU.0000000000003992 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Christine Kang James Yuheng Jiang Marco Enoch Lee Lily Shen Robert Mansberg Source Type: research

Tubercular Spondylitis: A Rare Complication of BCGosis Masquerading as Metastasis on 18F-PSMA-1007 PET/CT
We present a patient with incidental detection of abnormal uptake in a vertebral lesion during assessment of prostate cancer with 18F-PSMA PET/CT, subsequently proven to be vertebral osteitis, likely due to BCG immunotherapy. The case highlights the role of interdisciplinary patient assessment to confirm nature of abnormal foci on 18F-PSMA PET/CT.PMID:35020662 | DOI:10.1097/RLU.0000000000003989 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Amit Bohil Nagabhushan Seshadri Nitika Rathi Rashika Fernando Sobhan Vinjamuri Source Type: research

MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
CONCLUSIONS: We provide evidence on the role of MALAT1 in PCa tumorigenesis and progression. Also, we identify a direct interaction between miR-423-5p and MALAT1, which results in the suppression of MALAT1 action in PCa.PMID:35016717 | DOI:10.1186/s13046-021-02233-w (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Carmela Ferri Anna Di Biase Marco Bocchetti Silvia Zappavigna Sarah Wagner Pauline Le Vu Amalia Luce Alessia Maria Cossu Jayakumar Vadakekolathu Amanda Miles David J Boocock Alex Robinson Melanie Schwerdtfeger Virginia Tirino Federica Papaccio Michele Car Source Type: research

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer
Clin Genitourin Cancer. 2021 Dec 10:S1558-7673(21)00235-4. doi: 10.1016/j.clgc.2021.12.004. Online ahead of print.NO ABSTRACTPMID:35016887 | DOI:10.1016/j.clgc.2021.12.004 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Jeroen van Dorp Maurits L van Montfoort Nick van Dijk Ingrid Hofland Jeantine M de Feijter Andries M Bergman Kees Hendricksen Henk G van der Poel Bas W G van Rhijn Michiel S van der Heijden Source Type: research

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
CONCLUSION: Like patients, different mCRPC cell lines exhibit significant variability regarding CDDP tolerance. The presented in vitro data suggest that previous radiation treatment may be associated with a moderate sensitization to CDDP in an isogenic and age-matched setting. Therefore, previous radiotherapy or docetaxel chemotherapy might be no contraindication against initiation of platinum chemotherapy in selected mCRPC patients.PMID:35020044 | DOI:10.1007/s00432-022-03914-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Lukas Donix Holger H H Erb Claudia Peitzsch Anna Dubrovska Manuel Pfeifer Christian Thomas Susanne Fuessel Kati Erdmann Source Type: research

Cancer statistics, 2022
CA Cancer J Clin. 2022 Jan 12. doi: 10.3322/caac.21708. Online ahead of print.ABSTRACTEach year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 6...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Rebecca L Siegel Kimberly D Miller Hannah E Fuchs Ahmedin Jemal Source Type: research

68Ga-PSMA-11 PET Identified Tumor Recurrence in Prostatectomy Bed With Rising PSA of 0.9 ng/mL but Negative on MRI and 18F-Fluciclovine PET Scan
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003994. Online ahead of print.ABSTRACTA 63-year-old man with prostate cancer was treated with prostatectomy who had postoperative PSA of 0.6 ng/mL. A pelvic MRI, whole body bone scan, CT chest and abdomen exams did not show any residual or metastatic prostate disease. His PSA increased to 0.9 ng/mL in two months. A fluciclovine PET did not show any tracer avid metastatic or recurrent disease. A 0.7 cm non-fluciclovine-avid nodule at the left prostatectomy bed was considered benign. A 68Ga-PSMA-11 PET one month later showed avid radiotracer uptake within this nodule. Th...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Guofan Xu Yang Lu Source Type: research

Incidental Finding of Testicular Seminoma by 18F-Choline PET/CT in a Prostate Cancer Patient
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003988. Online ahead of print.ABSTRACTAn 80-year-old man with a history of prostate cancer, treated with radical prostatectomy and bilateral obturator nodal dissection, underwent an 18F-choline PET/CT because of biochemical recurrence. The scan revealed an intense focal uptake in the right testicle. A subsequent orchifunicumlectomy demonstrated the presence of a classic seminoma. At present, 18F-FDG PET/CT is useful for initial staging of testicular cancer and determining the viability of residual masses>3 cm after completion of treatment, especially in patients wit...
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Anna Calabr ò Giovanni Bosio Emma Drera Raffaele Giubbini Francesco Bertagna Source Type: research

68Ga-DOTATATE and 68Ga-PSMA Uptake in Granulomatous Prostatitis
We report a case of a 78-year-old man with prostate lesions showing intense uptake of 18FDG, 68Ga-PSMA, and 68Ga-DOTATATE simultaneously, with heterogeneous enhancement on contrast-enhanced CT and abnormal signal changes on PET/MRI. It was finally diagnosed as granulomatous prostatitis. This case suggests that granulomatous prostatitis has a high uptake of various imaging agents and is easily misdiagnosed as prostate cancer.PMID:35020658 | DOI:10.1097/RLU.0000000000003971 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Dan Ruan Long Sun Source Type: research

Incidental Intrahepatic Hepatocellular Cholangiocarcinoma Detected on 68Ga-PSMA PET/CT
Clin Nucl Med. 2022 Jan 11. doi: 10.1097/RLU.0000000000003992. Online ahead of print.ABSTRACTA 69-year-old man with intermediate-risk prostate cancer and a mildly elevated prostate-specific antigen of 8.2 μg/L was referred for 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT for primary staging. An incidental intensely 68Ga-PSMA-avid hepatic focus was seen on PSMA PET and subsequent FDG PET/CT and MRI cholangiogram. This was confirmed to be hepatocellular cholangiocarcinoma on subsequent histopathological examination.PMID:35020661 | DOI:10.1097/RLU.0000000000003992 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Christine Kang James Yuheng Jiang Marco Enoch Lee Lily Shen Robert Mansberg Source Type: research

Tubercular Spondylitis: A Rare Complication of BCGosis Masquerading as Metastasis on 18F-PSMA-1007 PET/CT
We present a patient with incidental detection of abnormal uptake in a vertebral lesion during assessment of prostate cancer with 18F-PSMA PET/CT, subsequently proven to be vertebral osteitis, likely due to BCG immunotherapy. The case highlights the role of interdisciplinary patient assessment to confirm nature of abnormal foci on 18F-PSMA PET/CT.PMID:35020662 | DOI:10.1097/RLU.0000000000003989 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 12, 2022 Category: Cancer & Oncology Authors: Amit Bohil Nagabhushan Seshadri Nitika Rathi Rashika Fernando Sobhan Vinjamuri Source Type: research

Bicalutamide Exhibits Potential to Damage Kidney via Destroying Complex I and Affecting Mitochondrial Dynamics
J Clin Med. 2021 Dec 27;11(1):135. doi: 10.3390/jcm11010135.ABSTRACTBicalutamide (Bic) is an androgen deprivation therapy (ADT) for treating prostate cancer, while ADT is potentially associated with acute kidney injury. Previously, we recognized Bic induced renal mitochondria dysfunction in vitro and in vivo via the ROS -HIF1α pathway. Whether OXPHOS complex, as well as mitochondrial dynamics, can be influenced by Bic via modulation of peroxisome proliferator-activated receptor coactivator 1α (PGC1α), NADPH oxidase 4 (Nox4), mitofusins 1/2 (MFN 1/2), optic atrophy 1 (OPA1), and sirtuins (SIRTs) has not be...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Kuan-Chou Chen Chang-Rong Chen Chang-Yu Chen Chiung-Chi Peng Robert Y Peng Source Type: research

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
J Clin Med. 2021 Dec 29;11(1):160. doi: 10.3390/jcm11010160.ABSTRACTDeregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Ak...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Anis Gasmi Guilhem Roubaud Charles Dariane Eric Barret Jean-Baptiste Beauval Laurent Brureau Gilles Cr éhange Ga ëlle Fiard Ga ëlle Fromont Mathieu Gauth é Alain Ruffion Rapha ële Renard-Penna Paul Sargos Morgan Roupr êt Guillaume Ploussard Romain M Source Type: research

Impact of the COVID-19 Pandemic on Urologic Oncology Surgery: Implications for Moving Forward
J Clin Med. 2021 Dec 29;11(1):171. doi: 10.3390/jcm11010171.ABSTRACTThe COVID-19 pandemic has caused the destruction of routine hospital services globally, leading to an increase in the backlog of elective surgery cases. The aim of the study was to retrospectively investigate the pandemic's impact on the urologic oncology surgical activity of a high-volume center located in Milan, Italy. The number and type of procedures performed in 2020 during the COVID-19 pandemic was evaluated using 2019 data as control. Waiting times for each surgical procedure were compared, on a bimonthly basis, between the two different years. Over...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Rossella Guerrieri Lucrezia Rovati Paolo Dell'Oglio Antonio Galfano Luca Ragazzoni Paolo Aseni Source Type: research

Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR
J Clin Med. 2022 Jan 4;11(1):257. doi: 10.3390/jcm11010257.ABSTRACTAndrogen Receptor (AR) alterations (amplification, point mutations, and splice variants) are master players in metastatic castration resistant prostate cancer (CRPC) progression and central therapeutic targets for patient management. Here, we have developed two multiplexed droplet digital PCR (ddPCR) assays to detect AR copy number (CN) and the key point mutation T877A. Overcoming challenges of determining gene amplification from liquid biopsies, these assays cross-validate each other to produce reliable AR amplification and mutation data from plasma cell f...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Francis P Young Therese M Becker Mohammed Nimir Thomas Opperman Wei Chua Bavanthi Balakrishnar Paul de Souza Yafeng Ma Source Type: research

Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice
CONCLUSION: Helix addressed multiple GT knowledge and practice gaps across a spectrum of providers. This tool will become publicly available soon to facilitate PCA GT in clinical practice.PMID:35012874 | DOI:10.1016/j.clgc.2021.11.009 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Veda N Giri Alexander Walker Laura Gross Edouard J Trabulsi Costas D Lallas William K Kelly Leonard G Gomella Corey Fischer Stacy Loeb Source Type: research

Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups
This article provides guidance regarding clinical trial design and conduct, and the interpretation of trial results.PMID:35015566 | DOI:10.1200/JCO.21.02440 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Heiko Sch öder Thomas A Hope Michael Knopp William K Kelly Jeff M Michalski Seth P Lerner Abdul Tawab-Amiri Bhupinder S Mann Daniel W Lin Evan Y Yu Ronald C Chen Gillian C Beach Steven A Reeves Members of the Working Group Lalitha K Shankar Source Type: research

Bicalutamide Exhibits Potential to Damage Kidney via Destroying Complex I and Affecting Mitochondrial Dynamics
J Clin Med. 2021 Dec 27;11(1):135. doi: 10.3390/jcm11010135.ABSTRACTBicalutamide (Bic) is an androgen deprivation therapy (ADT) for treating prostate cancer, while ADT is potentially associated with acute kidney injury. Previously, we recognized Bic induced renal mitochondria dysfunction in vitro and in vivo via the ROS -HIF1α pathway. Whether OXPHOS complex, as well as mitochondrial dynamics, can be influenced by Bic via modulation of peroxisome proliferator-activated receptor coactivator 1α (PGC1α), NADPH oxidase 4 (Nox4), mitofusins 1/2 (MFN 1/2), optic atrophy 1 (OPA1), and sirtuins (SIRTs) has not be...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Kuan-Chou Chen Chang-Rong Chen Chang-Yu Chen Chiung-Chi Peng Robert Y Peng Source Type: research

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
J Clin Med. 2021 Dec 29;11(1):160. doi: 10.3390/jcm11010160.ABSTRACTDeregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Ak...
Source: Clinical Prostate Cancer - January 11, 2022 Category: Cancer & Oncology Authors: Anis Gasmi Guilhem Roubaud Charles Dariane Eric Barret Jean-Baptiste Beauval Laurent Brureau Gilles Cr éhange Ga ëlle Fiard Ga ëlle Fromont Mathieu Gauth é Alain Ruffion Rapha ële Renard-Penna Paul Sargos Morgan Roupr êt Guillaume Ploussard Romain M Source Type: research